Government of Vietnam   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Hanoi Vietnam (1945)

Organization Overview

First Clinical Trial
2001
NCT00131820
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Company for vaccine and biological production No 1, Ministry of Health, Vietnam | Ho Chi Minh City CDC | Ministry of Health of Vietnam | Ministry of Health, Vietnam | Ministry of Science and Technology, Vietnam | National Geriatric Hospital | National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam | National Institute of Hygiene and Epidemiology, Vietnam | Vietnam Administration for HIV/AIDS Control (VAAC) | Vietnam: Ministry of Health | Vietnam National Cancer Hospital

Active Ingredients

Drugs in Phase 4 Trials (7)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil) (1 trial)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

pneumococcal 7-valent conjugate vaccine (Prevnar) (1 trial)

typhoid vi polysaccharide vaccine (Typhim Vi) (1 trial)

Drugs in Phase 3 Trials (8)

diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

inactivated influenza vaccine (3 trials)

inactivated japanese encephalitis vaccine (Ixiaro) (3 trials)

jecevax (3 trials)

live attenuated chimeric japanese encephalitis vaccine (1 trial)

matrix m1 (3 trials)

rotavin (3 trials)

Drugs in Phase 2 Trials (14)

bnt162b2 (Comirnaty) (1 trial)

buprenorphine (1 trial)

ch1701 (1 trial)

chloroquine (1 trial)

COVID-19 convalescent plasma (2 trials)

covid-19 vaccine hipra (1 trial)

CoviVac (1 trial)

human rotavirus, live attenuated (Rotarix) (1 trial)

killed oral cholera vaccine (1 trial)

methadone (methadose) (1 trial)

naloxone (narcan) (1 trial)

naltrexone (revia) (1 trial)

phosphate (1 trial)

polio, inactivated poliovirus vaccine (Salk Vaccine) (1 trial)

Drugs in Other Trials (2)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

salmon proteoglycan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholera (Phase 2)

Diarrhea (Phase 3)

Diphtheria (Phase 3)

Encephalitis (Phase 3)

Encephalitis, Japanese (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Infections (Phase 2)

Influenza, Human (Phase 3)

Influenza in Birds (Phase 3)

Nausea (Phase 3)

Paratyphoid Fever (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Poliomyelitis (Phase 3)

Tetanus (Phase 3)

Typhoid Fever (Phase 4)

Whooping Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 31